Trial Profile
ASP3550 Phase III Study - An Open-Label, Active-Controlled, Parallel-Arm Study, Comparing ASP3550 With Goserelin Acetate in Patients With Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Goserelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Astellas Pharma
- 01 Jun 2018 Results published in the Cancer Science
- 07 Sep 2016 Status changed from active, no longer recruiting to completed.
- 09 Jun 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.